Imaging-guided biopsy of 18F-FDG-Avid extrapulmonary lesions: Do lesion location and morphologic features on CT affect the positive predictive value for malignancy?

American Journal of Roentgenology

Volumn 201, Issue 2, 2013, Pages 433-438

  Nguyen, My Linh ^a,b   Gervais, Debra A ^b   Blake, Michael A ^b   Mueller, Peter R ^b   Sahani, Dushyant V ^b   Hahn, Peter F ^b   Uppot, Raul N ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

18F fluorodeoxyglucose; Imaging guided biopsy; Interventional radiology, nuclear medicine, PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADRENAL CORTEX ADENOMA; ADULT; AGED; ARTICLE; BENIGN TUMOR; BONE; CANCER LOCALIZATION; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HIBERNOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE GUIDED BIOPSY; INFLAMMATION; LEIOMYOMA; LIVER; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEURILEMOMA; NEUROFIBROMA; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THYROID NODULE; WARTHIN TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CHI-SQUARE DISTRIBUTION; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOGRAPHY, INTERVENTIONAL; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 84883694245     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.12.9166     Document Type: Article

References (31)

1. Blake MA, Singh A, Setty BN, et al. Pearls and pitfalls in interpretation of abdominal and pelvic PET-CT. RadioGraphics 2006; 26:1335-1353
2. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: A meta-Analysis. JAMA 2001; 285:914-924
3. Metser U, Even-Sapir E. The role of 18F-FDG PET/CT in the evaluation of solid splenic masses. Semin Ultrasound CT MR 2006; 27:420-425
4. Shin DS, Shon OJ, Han DS, Choi JH, Chun KA, Cho IH. The clinical efficacy of 18F-FDG-PET/CT in benign and malignant musculoskeletal tumors. Ann Nucl Med 2008; 22:603-609
5. Rebollo Aguirre AC, Ramos-Font C, Villegas Portero R, Cook GJ, Llamas Elvira JM, Tabares AR. 18F-fluorodeoxiglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer: Systematic review of the literature. Ann Surg 2009; 250:247-254
6. Ciocca V, Miller MC, Keane WM, Bibbo M. Correlation of positron emission tomography with fine needle aspiration biopsies in head and neck malignancy. Acta Cytol 2010; 54:5-11
7. Collins BT, Gardner LJ, Verma AK, Lowe VJ, Dunphy FR, Boyd JH. Correlation of fine needle aspiration biopsy and fluoride-18 fluorodeoxyglucose positron emission tomography in the assessment of locally recurrent and metastatic head and neck neoplasia. Acta Cytol 1998; 42: 1325-1329
8. Huebner RH, Park KC, Shepherd JE, et al. A meta-Analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000; 41:1177-1189
9. Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC. 18F-fluoro-deoxyglucose positron emission tomography for posttreatment evaluation of malignant lymphoma: A systematic review. Haematologica 2006; 91:522-529
10. van Westreenen HL, Westerterp M, Bossuyt PM, et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 2004; 22:3805-3812
11. Wong RJ, Lin DT, Schoder H, et al. Diagnostic and prognostic value of [18F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002; 20:4199-4208
12. Yen RF, Hung RL, Pan MH, et al. 18-Fluoro- 2-deoxyglucose positron emission tomography in detecting residual/recurrent nasopharyngeal carcinomas and comparison with magnetic resonance imaging. Cancer 2003; 98:283-287
13. Shim SS, Lee KS, Kim BT, et al. Non-small cell lung cancer: Prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 2005; 236:1011-1019
14. Branstetter BF 4th, Blodgett TM, Zimmer LA, et al. Head and neck malignancy: Is PET/CT more accurate than PET or CT alone? Radiology 2005; 235:580-586
15. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42(suppl 5): 1S-93S
16. Taira AV, Herfkens RJ, Gambhir SS, Quon A. Detection of bone metastases: Assessment of integrated FDG PET/CT imaging. Radiology 2007; 243:204-211
17. Tatsumi M, Miller JH, Wahl RL. 18F-FDG PET/CT in evaluating non-CNS pediatric malignancies. J Nucl Med 2007; 48:1923-1931
18. Pansare V, Bandyopadhyay S, Feng J, et al. Fine needle aspiration outcomes of masses detected by positron emission tomography: Correlation with standard uptake value. Acta Cytol 2007; 51:509-516
19. Sacks D, McClenny TE, Cardella JF, Lewis CA. Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol 2003; 14:S199-S202
20. Sahani DV, Kalva SP, Fischman AJ, et al. Detection of liver metastases from adenocarcinoma of the colon and pancreas: Comparison of mangafodipir trisodium-enhanced liver MRI and wholebody FDG PET. AJR 2005; 185:239-246
21. Böhm B, Voth M, Geoghegan J, et al. Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors. J Cancer Res Clin Oncol 2004; 130:266-272
22. Ramos E, Valls C, Martinez L, et al. Preoperative staging of patients with liver metastases of colorectal carcinoma: Does PET/CT really add something to multidetector CT? Ann Surg Oncol 2011; 18:2654-2661
23. Servois V, Mariani P, Malhaire C, et al. Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET). Eur J Surg Oncol 2010; 36: 189-194
24. Tian R, Su M, Tian Y, et al. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions. Skeletal Radiol 2009; 38:451-458
25. Pezeshk P, Sadow CA, Winalski CS, Lang PK, Ready JE, Carrino JA. Usefulness of 18F-FDG PET-directed skeletal biopsy for metastatic neoplasm. Acad Radiol 2006; 13:1011-1015
26. Kobayashi S, Nagano H, Hoshino H, et al. Diagnostic value of FDG-PET for lymph node metastasis and outcome of surgery for biliary cancer. J Surg Oncol 2011; 103:223-229
27. Lee MJ, Yun MJ, Park MS, et al. Paraaortic lymph node metastasis in patients with intra-Abdominal malignancies: CT vs PET. World J Gastroenterol 2009; 15:4434-4438
28. Metser U, You J, McSweeney S, Freeman M, Hendler A. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen. AJR 2010; 194:766-771
29. Yao M, Smith RB, Hoffman HT, Funk GF, Graham MM, Buatti JM. Merkel cell carcinoma: Two case reports focusing on the role of fluorodeoxyglucose positron emission tomography imaging in staging and surveillance. Am J Clin Oncol 2005; 28:205-210
30. Knight SB, Delbeke D, Stewart JR, Sandler MP. Evaluation of pulmonary lesions with FDGPET: Comparison of findings in patients with and without a history of prior malignancy. Chest 1996; 109:982-988
31. Lee J, Aronchick JM, Alavi A. Accuracy of F-18 fluorodeoxyglucose positron emission tomography for the evaluation of malignancy in patients presenting with new lung abnormalities: A retrospective review. Chest 2001; 120:1791-1797